What is the real clinical therapeutic effect of Pimetibi?
Pimitespib is a small molecule inhibitor targeting HSP90 (heat shock protein 90). As the first drug of this type to be marketed in Japan, it is mainly used to treat advanced gastrointestinal stromal tumors (GIST) that are refractory to standard therapies. Its unique mechanism of action allows it to show interesting clinical potential in some refractory solid tumors, especially after the failure of chemotherapy, tyrosine kinase inhibitors (TKIs) and other treatments, it still provides patients with hope for survival beyond the first line.

From the perspective of its mechanism of action,HSP90 is an important molecular chaperone that maintains the stability of kinesins in various cancers. By inhibiting HSP90, Pimitespib can promote the degradation of a series of oncogenic proteins and block the proliferation and survival pathways of cancer cells from the source. In real-world clinical observations, Pimitespib has shown good disease control rates in some GIST patients. Especially for those advanced patients who have developed resistance to imatinib, sunitinib and regorafenib, it still has the potential to alleviate the disease.
What is more noteworthy is that Pimitespib’s oral administration method provides greater convenience for patients, and has been optimized in terms of toxicity control compared with early HSP90 inhibitors, such as less common severe liver toxicity or cardiac toxicity, which helps to improve patients’ medication compliance. Some patients mainly experience mild to moderate fatigue, nausea, loss of appetite and other adverse reactions during medication, which can often be relieved through dose adjustment or adjuvant treatment.
Although currentlyPimitespib is still mainly used in the field of GIST, but as research advances, it may expand its indications in other solid tumors. The continuous accumulation of real-world data also provides theoretical support for the use of drugs by a wider range of people in the future.
Reference materials:https://en.wikipedia.org/wiki/Pimitespib
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)